- Home
- IPHA vs FCCO Comparison
IPHA vs FCCO Comparison
Compare IPHA & FCCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- FCCO
- Stock Information
- Founded
- IPHA 1999
- FCCO 1994
- Country
- IPHA France
- FCCO United States
- Employees
- IPHA N/A
- FCCO N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- FCCO Major Banks
- Sector
- IPHA Health Care
- FCCO Finance
- Exchange
- IPHA Nasdaq
- FCCO Nasdaq
- Market Cap
- IPHA 148.3M
- FCCO N/A
- IPO Year
- IPHA 2019
- FCCO 1998
- Fundamental
- Price
- IPHA $1.79
- FCCO $22.97
- Analyst Decision
- IPHA Strong Buy
- FCCO Buy
- Analyst Count
- IPHA 1
- FCCO 1
- Target Price
- IPHA $11.50
- FCCO $21.00
- AVG Volume (30 Days)
- IPHA 779.8K
- FCCO 31.8K
- Earning Date
- IPHA 09-12-2024
- FCCO 01-22-2025
- Dividend Yield
- IPHA N/A
- FCCO 2.63%
- EPS Growth
- IPHA N/A
- FCCO 2.46
- EPS
- IPHA N/A
- FCCO 1.69
- Revenue
- IPHA $36,202,722.00
- FCCO $62,732,000.00
- Revenue This Year
- IPHA N/A
- FCCO N/A
- Revenue Next Year
- IPHA $101.65
- FCCO $11.21
- P/E Ratio
- IPHA N/A
- FCCO $13.19
- Revenue Growth
- IPHA N/A
- FCCO 6.16
- 52 Week Low
- IPHA $1.29
- FCCO $15.40
- 52 Week High
- IPHA $3.51
- FCCO $26.48
- Technical
- Relative Strength Index (RSI)
- IPHA 45.92
- FCCO 35.98
- Support Level
- IPHA $1.64
- FCCO $22.11
- Resistance Level
- IPHA $1.87
- FCCO $24.07
- Average True Range (ATR)
- IPHA 0.12
- FCCO 0.45
- MACD
- IPHA -0.04
- FCCO -0.18
- Stochastic Oscillator
- IPHA 28.66
- FCCO 36.29
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.